Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma's Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial
During the R&D event for investors, Rhythm Pharmaceuticals Inc RYTM released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or proopiomelanocortin (POMC) or leptin receptor (LEPR)…
#rytm #bardetbiedl #pomc #lepr #bmiz #bmi #304 #newdrugapplication #fda #phase1